Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 17,846 matching trials from the live ClinicalTrials.gov search.
Conditions
Cystic Fibrosis, Cystic Fibrosis in Children
Interventions
Not listed
Lead sponsor
Nicole Hamblett
Other
Eligibility
6 Years to 11 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
20
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 17 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BOTOX® (onabotulinumtoxinA) Treatment of Masseter Muscle Prominence

NCT03861936
Conditions
Masseter Muscle Prominence
Interventions
OnabotulinumtoxinA, Normal saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 10 more
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Pulmonary Complications, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Neuroblastoma, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
etanercept, methylprednisolone
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Arcadia, California • Loma Linda, California + 22 more
Conditions
Transfusional Hemosiderosis
Interventions
deferasirox:
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Oakland, California • Palo Alto, California • Pleasant Hill, California + 19 more
Conditions
Chronic Graft Versus Host Disease
Interventions
ibrutinib, Placebo, Prednisone
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
12 Years and older
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
38
States / cities
Scottsdale, Arizona • Palo Alto, California • San Francisco, California + 29 more
Conditions
Gastrointestinal Dysmotility
Interventions
Saline Solution for Injection, Ipamorelin
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
45
States / cities
Florence, Alabama • Sheffield, Alabama • Fountain Valley, California + 42 more
Conditions
Cholangiocarcinoma
Interventions
Nab-Paclitaxel and Gemcitabine
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
24
States / cities
Denver, Colorado • Chicago, Illinois • Oak Lawn, Illinois + 17 more
Conditions
Multiple Myeloma
Interventions
filgrastim, cisplatin, cyclophosphamide, dexamethasone, etoposide, thalidomide
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
93
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Conditions
End Stage Kidney Disease, Depressive Symptoms
Interventions
Joviality(TM), Inert Virtual Reality
Behavioral · Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois
Conditions
Non-small Cell Lung Cancer
Interventions
Other
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Anaheim, California • Los Angeles, California • Santa Rosa, California + 16 more
Conditions
Metastatic Breast Cancer
Interventions
Placebo, Veliparib, Carboplatin, Temozolomide, Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
34
States / cities
Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more
Conditions
Covid19
Interventions
TM5614, Placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Chicago, Illinois
Not listed Not applicable Interventional Accepts healthy volunteers

Repetitive Acute Intermittent Hypoxia for Spinal Cord Repair

NCT03433599
Conditions
Spinal Cord Injuries
Interventions
Repeated exposure to acute Intermittent Hypoxia (rAIH), Normal Room Air, Upper-limb Training by Research Staff, Lower-limb Training by Research Staff
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
61
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 55 more
Completed No phase listed Observational Accepts healthy volunteers

Bipolar and Schizophrenia Consortium for Parsing Intermediate Phenotypes

NCT00666432
Conditions
Schizophrenia, Bipolar
Interventions
This is an observational study model that is family based
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
15 Years and older
Enrollment
3,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Chicago, Illinois • Baltimore, Maryland + 2 more
Conditions
Septic Shock
Interventions
Hydrocortisone, sodium succinate, Normal saline
Drug
Lead sponsor
Jerry Zimmerman
Other
Eligibility
1 Month to 17 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
18
States / cities
Tucson, Arizona • Los Angeles, California • Oakland, California + 15 more
Conditions
Barrett's Esophagus, Esophageal Neoplasms
Interventions
Radiofrequency Ablation(RFA) by HALO device., Endoscopic mucosal resection(EMR) by mucosectomy kit.
Device
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • St Louis, Missouri • New York, New York
Conditions
Bronchospasm, Activity/Exercise Induced Bronchospasm
Interventions
Fluticasone propionate/salmeterol, Fluticasone Propionate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 17 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
50
States / cities
Little Rock, Arkansas • Huntington Beach, California • Orange, California + 45 more
Conditions
High Risk Acute Myeloid Leukemia
Interventions
CPX-351, 7+3 (cytarabine and daunorubicin)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
60 Years to 75 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 31 more
Conditions
Achromatopsia
Interventions
Not listed
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
5
States / cities
Gainesville, Florida • Miami, Florida • Chicago, Illinois + 2 more
Conditions
Ovarian Carcinoma
Interventions
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging
Procedure · Other
Lead sponsor
NRG Oncology
Other
Eligibility
35 Years to 50 Years · Female only
Enrollment
1,956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2047
U.S. locations
620
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 406 more
Conditions
HIV Infections, Hepatitis C
Interventions
Pegylated-Interferon Alfa 2b (PEG-IFN), Ribavirin (RBV), Boceprevir (BOC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 30 more
Conditions
Sarcopenia
Interventions
Resistance exercise
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
65 Years to 100 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Breast Cancer
Interventions
Gemcitabine, Sorafenib, Placebo, Capecitabine
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
44
States / cities
Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 37 more